Welcome to our dedicated page for Nutra Pharma news (Ticker: NPHC), a resource for investors and traders seeking the latest updates and insights on Nutra Pharma stock.
Nutra Pharma Corp (NPHC) is a biotechnology innovator developing treatments for neurological disorders, chronic pain, and complex diseases through strategic pharmaceutical licensing. This page aggregates all company announcements and news updates for investors and industry observers.
Access official press releases covering clinical trial progress, regulatory filings, and partnership developments. Track updates across NPHC's therapeutic focus areas including non-opioid pain management, autoimmune therapies, and veterinary pharmaceuticals. Key content includes earnings reports, product launch details, and research milestones.
Bookmark this page for streamlined monitoring of NPHC's progress in drug commercialization and licensing agreements. Check regularly for verified updates on their pain relief products like Nyloxin and Pet Pain-Away, plus emerging therapies in development.
Nutra Pharma announces Avini Health as its first contract manufacturing partner.
On March 23, 2022, Nutra Pharma Corporation (OTC Pink: NPHC) disclosed its agreement with Avini Health to offer formulation and manufacturing services. CEO Rik J Deitsch highlighted this partnership as a potential revenue stream while optimizing production costs through economies of scale. Avini Health, focused on holistic products, aims to leverage Nutra's expertise in product development. The companies expect significant revenue growth from this collaboration over the upcoming quarters.
Nutra Pharma has announced significant enhancements to its manufacturing capabilities, aiming for improved product launches in the OTC drug and dietary supplement markets. Recent upgrades include a liquid filling line, tube-filling, capsule-filling machine, and extrusion line. These developments align with Nutra Pharma's strategy to reduce costs, increase margins, and expedite product innovation. The CEO emphasizes the importance of bringing manufacturing back to the U.S. and aims to act as a contract manufacturer for OTC products. Further updates on product launches and manufacturing capabilities are expected throughout 2022.
Nutra Pharma Corporation (NPHC) has released its annual letter to shareholders, highlighting optimism for 2022 following challenges in 2021. CEO Rik J Deitsch emphasized plans to increase manufacturing, launch new products, and expand marketing efforts. Key accomplishments include a renewed focus on intellectual property, in-house manufacturing enhancements, and the launch of Luxury Feet for pain relief. The letter also notes partnerships with influencers for marketing and private label agreements aimed at boosting sales.
Nutra Pharma Corporation (OTC Pink: NPHC) announced updates on its business plans and compliance efforts. The CEO, Rik J Deitsch, highlighted progress in filing overdue reports and improving transparency, stating that six reports were filed since February 2021. The company is amplifying brand awareness through marketing initiatives and enhancing manufacturing capabilities. Additionally, Nutra Pharma is focused on acquiring new patents and government contracts to boost its operations in treating neurological disorders, cancer, and pain management.
Nutra Pharma has filed an updated provisional patent to protect its intellectual property related to RPI-78M and analogs as potential counter-measures against organophosphate nerve agents. CEO Rik J Deitsch highlighted the project's goal to mitigate damage from chemical weapons like sarin and VX. The drug RPI-78M targets receptors disrupted by nerve agents and has demonstrated a low toxicity profile. The company aims to collaborate with governmental and private entities to advance research and potentially license the technology, which is timely given the increasing use of nerve agents.
Nutra Pharma Corporation (OTC Pink: NPHC) announced its partnership with Vitello Consulting, a government affairs firm, to enhance awareness of its pain relief products including Nyloxin®. This collaboration aims to improve sales, secure grants, and expedite drug applications, particularly targeting Veterans Administration facilities. Nutra Pharma is also pursuing clinical trials for its RPI-78M drug for multiple sclerosis, which has received FDA Orphan Designation. The company emphasizes its commitment to providing effective pain relief without cognitive impairment.
